Portland, OR -- (SBWIRE) -- 05/10/2019 -- According to a new report published by Allied Market Research, titled, Over the Counter (OTC) Drugs & Dietary Supplements Market by Category, Dosage Form, Product, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global over the counter (OTC) drugs & dietary supplements market was valued at $223 million in 2016, and is projected to reach $335 million by 2023, growing at a CAGR of 5.9% from 2017 to 2023. The vitamins and dietary supplements (VDS) segment accounted for maximum share of about half the global market share in 2016.

In 2016, Asia-Pacific and LAMEA collectively accounted for about half share of the global market, and is expected to continue this trend throughout the forecast period. The factors driving the market growth include increase in awareness about OTC drugs, dietary supplements, and occurrence of common ailments such as cold & cough, infectious diseases, oral diseases, and others. In addition, increase in the availability of these drugs specifically in China, India, and the other developing economies to meet the growing demand for OTC products is expected to drive the market growth. Moreover, large population base and growth in economy catering to the establishment of healthcare facilities boost the market growth.

https://www.alliedmarketresearch.com/request-sample/2695 " href="https://www.alliedmarketresearch.com/request-sample/2695">Download Sample PDF Brochure at: https://www.alliedmarketresearch.com/request-sample/2695

The report provides a comprehensive analysis of the key players operating in the global market such as Pfizer Inc., Novartis International AG., Roche Holding AG, Merck & Co., Inc., Sanofi S.A, Johnson & Johnson, Gilead Sciences, GlaxoSmithKline plc., Bayer Healthcare AG, and AstraZeneca plc.

The other players in the value chain of the global market include Allergan, Plc., Reckitt Benckiser Plc., AbbVie Inc., Sun Pharma, Daiichi Sankyo Co., Ltd., Alcon Inc., Alfresa Pharma Corporation, Alkalon A/S, Alliance Healthcare, and Allergan, Plc.

Over the counter (OTC) drugs are basically non-prescription medicines, which are sold without the doctors prescription. Hence, retrieving OTC drugs has become an easy task due to the wide availability of OTC drugs in pharmacies and online health websites. In addition, OTC drugs are regulated by active pharmaceutical ingredients (APIs) and not by the final product. Moreover, dietary supplements are intended to deliver desired nutrients to the body to increase the quantity of an individuals diet consumption. Furthermore, these supplements provide additional non-nutrient chemicals, which are claimed to have biologically beneficial effects in the body.

The global market is driven by improvement in lifestyle & ageing of baby boomers, rise in awareness about general health concerns, and increase in trend among individuals to opt for OTC drugs for self-medication. However, strict regulations by governing bodies, such as FDA, have led to the delayed approval of drugs, restraining the market growth. Conversely, several key players have undertaken R&D activities to enhance OTC drugs for the treatment of various ailments such as laxatives, oral antiseptics, analgesics, and anti-smoking products, providing opportunities for the market players.

https://www.alliedmarketresearch.com/purchase-enquiry/2695 " href="https://www.alliedmarketresearch.com/purchase-enquiry/2695">Do Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2695

The cough & cold products segment is expected to grow at a robust CAGR of 6.1% from 2017 to 2023, owing to blockbuster sales of these drugs. As cold & cough is the most commonly acquired ailment among all age groups across the globe, the sales of OTC drugs has increased in the recent years. Gastrointestinal products are the attractive segment due to increased OTC drug sales for treating gastrointestinal disorders such as diarrhea, constipation, indigestion, bouts of vomiting among others.

The tablets segment generated the highest revenue in 2016, accounting for about two-ninths share of the global market, and is expected to maintain this trend during the forecast period. This is due to high prevalence of diseases coupled with the advantages of consuming tablets and provision of accurate dosage level for different patient type. Furthermore, the soft capsules segment is expected to grow at the highest CAGR of 6.6% during the forecast period.

Key Benefits

- The study provides an in-depth analysis of the global over the counter (OTC) drugs & dietary supplements market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A quantitative analysis from 2016 to 2023 is discussed to enable stakeholders to capitalize on the prevailing market opportunities.
- Key market players are profiled and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
- Porters five forces model is expected to interpret the impact of bargaining power of suppliers & buyers, threat of new entrants & substitutes, and competition among the key players on the market growth.